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INTRODUCTION
As US President Barack Obama noted in his 2015 State of the Union address, preci-
sion medicine promises to deliver ‘the right treatments, at the right time, every time
to the right person’ which ‘gives us one of the greatest opportunities for new medical
breakthroughs that we have ever seen’.1 These comments were a prelude to a $215mil-
lion funding commitment by the President to his PrecisionMedicine Initiative, the aim
of which is to ‘pioneer a new model of patient-powered research that promises to ac-
celerate biomedical discoveries and provide clinicians with new tools, knowledge, and
therapies to select which treatments will work best for which patients’.2 The objectives
include an undertaking to modernize the current regulatory landscape.
Some six months prior to this address, a group of international scholars in the disci-
plines of law, biomedicine, bioethics, and the social sciencesmet at the other end of the
world inHobart, Australia to workshop the challenges involved in formulating a coher-
ent regulatory framework for precisionmedicine.The inspiration for theworkshop title,
Leading or Limping? Regulation of Personalized Medicine, came from a famous observa-
tion by one of Australia’s most eminent High Court judges, Justice VictorWindeyer in
the case ofMount Isa Mines Ltd v Pusey (1970) 125 CLR 383 at 395, where he referred
to the law as ‘marching with medicine but in the rear and limping a little’.The language
of personalized medicine, rather than precision medicine, was used at the workshop,
because at that time it was the more common term.3
The terms ‘precision’, ‘personalized’, and ‘medicine’ already hint at some of the reg-
ulatory challenges that lie ahead. ‘Precision’ implies that the product or service being
offered is accurate and targeted. Like any novel area, the frontier is often filled with a
health technologies, and legal aspects of health system reform. She is a recipient of the 2015–16 Australian
Fellowship in Health Services Research and Policy.
‡‡‡‡‡ Loane Skene is a Professor of Law in the Melbourne Law School and Adjunct Professor in the Faculty
of Medicine, Dentistry, and Health Sciences at the University of Melbourne in Australia. She has broad
research interests in health and medical law and has served on numerous Australian ethics and law reform
committees.
∗∗∗∗∗∗ Cameron Stewart is a Professor and Pro Dean at Sydney Law School, Australia. He is a member of the
Centre for Health Governance, Law and Ethics and an associate of the Centre for Values, Ethics and the
Law in Medicine, Sydney Medical School. He has broad research interests in health and medical law and
has served on a number of ethics and law reform committees.
†††††† JenniferWagner is the Associate Director of Bioethics Research for Geisinger Health System and is a prac-
ticing attorney in Pennsylvania, USA. She recently served as a 2014–2015 AAAS Science & Technology
Policy Fellow in a US Senator’s office. Her research has focused broadly on the intersections of anthropol-
ogy, genetics, and law. She has been particularly interested in DNA ancestry tests, personal genomics in
sports, human rights, and separation of powers issues.
‡‡‡‡‡‡ Nik Zeps is Director of Research at St John of God Perth Northern Hospitals. He has research inter-
ests in biobanking, clinical trials, and molecular pathology, as well as ethical regulation of use of human
biospecimens and associated clinical data and conduct of clinical trials. He is a founding director of the
Australian Clinical Trials Alliance and co-chair of the Communications Committee of the International
Cancer Genome Consortium for PrecisionMedicine.
1 Jocelyn Kaiser, Obama gives East Room Rollout to Precision Medicine Initiative, SCIENCE DOI: 10.1126/
science.aaa6436 (Jan. 30 2015).
2 The White House, Fact Sheet: President Obama’s Precision Medicine Initiative, https://www.whitehouse.
gov/the-press-office/2015/01/30/fact-sheet-president-obama-s-precision-medicine-initiative (accessed
April 23, 2016).
3 Sebastian Schleidgen et al.,What is Personalized Medicine: Sharpening a Vague Term Based on a Systematic
Literature Review, 14 BMC MED. ETHICS 55 (2013); see also US Food and Drugs Administration, Paving
the Way for Personalized Medicine: FDA’s Role in a New Era of Medical Product Development, 6 (2013).
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variety of new players some of whomwill see a huge commercial opportunity and may
push the boundaries of acceptability in terms of their claims. In addition, novel risks of
harm to individuals may rise or be exacerbated by the new technologies. We therefore
need to be assured that appropriate regulatory requirements are in place so that preci-
sion medicine can be undertaken efficiently and safely and in a manner that facilitates
the translation of research into effective therapies.
Language that focuses attentionon the ‘person’ immediately raises questions around
personhoodandprivacy.As knowledge andunderstandingof personal health increases,
so too do the potential threats to personal privacy. ‘Medicine’ implies that these new
advances sit within the established medical care system, with all the regulatory checks
and balances that go alongwith it. Yet, wewill see in the discussion that follows that one
of the features of precision medicine is the blurring of boundaries between the clinic,
the laboratory, and the healthcare industry, creating new regulatory spaces.4 On the
one hand, this raises questions about the capacity of existing regulatory structures to
respond. On the other hand, it risks regulatory overlap and confusion, a veritable ‘reg-
ulatory soup’ that could drown the promised advances in precision medicine.
Before we start to consider how precision medicine should be regulated, we need
to be clear about what we mean by regulation. Here, the broad approach as Roger
Brownsword andMorag Goodwin is adopted:
. . . we can treat ‘regulation’ as encompassing any instrument (legal or non-legal in its char-
acter, governmental or non-governmental in its source, direct or indirect in its operation,
and so on) that is designed to channel group behaviour; and we can treat as a ‘regulator’
any person or body who initiates regulation in this broad sense.5
In many ways, the regulatory challenges presented by precision medicine are re-
formulations of old tensions—community welfare versus individual liberty, risk versus
benefit, autonomy versus paternalism. The potential for precision medicine to exacer-
bate existing disparities in health care, bothwithin countries and internationally, should
also be at the forefront of our concerns.6
Here, we provide an overview of some of the more substantive issues that are likely
to arise in responding to the perceived need to modernize the current regulatory land-
scape for precision medicine. The issues considered are largely based on discussions
at the workshop, together with some of the more notable policy and academic com-
mentaries. In the first part of this essay, we outline some of the major technological
advances in the fields of precision medicine, including genome sequencing, pharma-
cogenomics, genomic analysis, gene editing, and biobanking.We go on to consider the
regulatory landscapes within which these technologies are positioned with particular
focus on what is needed to ensure that regulation is effective in the future.
4 On the broad concept of regulatory space seeColin Scott,Analysing Regulatory Space: Fragmented Resources
and Institutional Design, PUB. L, 329 (2001).
5 Roger Brownsword &Morag Goodwin, LAW AND THE TECHNOLOGIES OF THE TWENTY-FIRST CENTURY 25
(2012).
6 Kyle Brothers & Mark Rothstein, Ethical, Legal, and Social Implications of Incorporating Personalized
Medicine into Healthcare, 11 PERS. MED. 43 (2015).
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THE PROMISE OF PRECISION MEDICINE
Claims that precisionmedicinewill delivermore personalized healthcare, tailored to an
individual’s genetic characteristics, health status and family history, are supported by
several recent developments, particularly targeted therapies for the treatment of can-
cers.7 Some commentators, however, are skeptical about the extent to which precision
medicine research will, in the near future, be translated into genuine improvements in
the delivery of healthcare.8 Recognizing the need for dispassionate evaluation of the
promise of precision medicine, there is, nevertheless, little doubt that it sits within a
rapidly changing milieu, as illustrated in Fig. 1.
During the past two decades, new technological developments such as massively
parallel DNA sequencing have enabled high throughput analysis of DNA, RNA and
proteins.9 These developments have facilitated increased utilization of genetic and ge-
nomic information in the research context to provide valuable insights into the role of
these factors in human health and wellbeing. This same genetic and genomic informa-
tion is being used by clinicians in the delivery of healthcare, including assessing a per-
son’s predisposition to disease and assisting with their diagnosis and prognosis, as well
as informing treatment decisions.10 Whilstmanufacture of newdrugs has long been the
province of pharmaceutical companies, the commercial sector is becoming increasingly
involved in the delivery of healthcare, in particular diagnostic testing, once the exclusive
purview of the medical profession.
Genome sequencing advances
Continuing advances in genome sequencing technology, together with massive reduc-
tion in costs, are together allowingmultiple genetic variations to be assayed at the same
time, often for the same cost as a single gene test.11 Both whole exome sequencing (se-
quencing of the active components of human genes that code for proteins) and whole
genome sequencing (WGS) are now feasible.12 Given the possibility of extending test-
ing well beyond the gene of interest indicated by clinical assessments, there has been
7 Eric D. Green,Mark S. Guyer National HumanGenome Research Institute,Charting a Course for Genomic
Medicine from Base Paris to Bedside, 470 NATURE 204 (2011); see also Don Chalmers et al., Personalised
Medicine in the Genome Era, 20 J. L. &MED. 577 (2013).
8 See eg the British Medical Journal blog post by Tim Caulfield,Genetics and Personalized Medicine: Where’s
the Revolution, http://blogs.bmj.com/ce/2015/07/23/genetics-and-personalized-medicine-wheres-the-
revolution/?utm campaign=shareaholic&utm medium=twitter&utm source=socialnetwork (accessed
April 23, 2016) and articles in the popular press, Michael J. Joyner, ‘Moonshot’ Medicine Will Let Us Down,
N. Y. TIMES, 29 Jan. 2015; H Gilbert Welch &Wylie Burke,Why Whole Genome Testing Hurts More Than
It Helps, LOS ANGELES TIMES, 27 Apr. 2015.
9 Green, Guyer & National Human Genome Research Institute, supra note 7, at 205; Elaine S. Mardis, A
Decade’s Perspective on DNA Sequencing Technology, 470 NATURE 198 (2011); David AWheeler et al.,The
Complete Genome of an Individual by Massively Parallel DNA Sequencing, 452 NATURE 872 (2008).
10 Francis S. Collins & Harold Varmus, A New Initiative on Precision Medicine, 372 NEW ENG. J. MED 793
(2015).
11 These cost reductions were already having an impact as early as 2011. See eg Eric S. Lander, Initial Impact
of the Sequencing of the Human Genome, 470 NATURE 187 (2011).
12 For a useful overviewof the key differences betweenwhole genome and exome sequencing, see Illumina,An
Introduction to Next-generation Sequencing, http://www.illumina.com/content/dam/illumina-marketing/
documents/products/illumina sequencing introduction.pdf (accessed April 23, 2016).
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Figure 1. The changing milieu of healthcare. A. Traditional relationships between the
individual and biomedical sector participants. B. Changing relationships and
participants in the genomic era.
some debate as to whether there is a duty of care to assess all known genetic alterations
that may be present, in both the clinical and the research context.13
13 Robert C. Green et al., ACMG Recommendations for Reporting of Incidental Findings in Clinical Exome and
Genome Sequencing, 15 GENET. MED. 565 (2013); American College of Medical Genetics and Genomics,
Incidental Findings in Clinical Genomics: A Clarification, https://www.hgsa.org.au/documents/item/582
(accessed April 23, 2016); Madhuri Hegde et al., Reporting Incidental Findings in Genomic Scale Clinical
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This era of more rapid genomic analysis has also witnessed the expansion of the
for-profit private sector providing genomic services.14 One of the leading sequencing
companies, Illumina, is offering WGS to researchers and clinicians at rapidly reducing
prices. For example, in 2011 itwas offeringwhole tumor genome sequencing for around
US$30,000.15 By 2014, the company announced that its new sequencing technology
gave it the capacity to offer WGS for US$1,000.16 Although this figure does not fac-
tor in the significantly higher cost of bioinformatics analysis, ongoing improvements
in high-performance computing and analytical algorithms will see this cost continue to
decrease as well.17
It is timely, at this stage, to reflect on howwemight utilize the benefits resulting from
increased accuracy and efficiency and reduced costs of sequencing in away that benefits
society as a whole. As Tim Caulfield and colleagues point out:
Rapid, lower-cost WGS is a promising research tool with unproven clinical utility,
except in a small set of very specific situations. The journey from bench to bedside is
one we should travel with care. . . . The scale and pace of adoption of this powerful new
technology should be driven by clinical need, clinical evidence, and a commitment to
put patients at the centre of health care policy.18
These salutary words illustrate that we should not be taken in by the hype that in-
evitably accompanies each new technological development. Rather, we should take a
purposive approach, requiring clear evidence of safety and effectiveness, and, above all,
focusing on patients’ needs and interests.
Precision therapeutics—pharmacogenomics
The aim of pharmacogenomics is to combine targeted therapies with companion pre-
treatment diagnostic tests, which identify whether a person carries a gene or other
biomarker that is linkedwith increased sensitivity to or resistance to the particular treat-
ment.The starting point is improved understanding of how genetic variations within a
population affect responses to particular drugs.19Themost rapid advances have been in
the field ofmolecular pathology and development of targeted cancer therapies. 20 Fran-
cis Collins andHarold Varmus, Directors of theUSNational Institutes ofHealth of the
National Cancer Institute respectively, point out that the fact that cancers have their
own heterogeneous genomic signatures opens avenues to the development of many
more of targeted therapies.21 But at the same time, this illustrates that the economic
Sequencing—A Clinical Laboratory Perspective: A Report of the Association for Molecular Pathology, 17 J.
MOLECULAR DIAGNOSTICS 107 (2015).
14 A number of for-profit companies were already well established during the period when publicly funded
research institutes around theworldwereworking towards the completion of theHumanGenomeProject.
See egRebecca Eisenberg,Genomics in the PublicDomain: Strategy and Policy 1NAT.REV.GENET. 20 (2000).
15 Mardis, supra note 9, at 199.
16 Erika C. Hayden, Is the $1,000 Genome for Real?NATURE DOI 10.1038/nature.2014.14530 (2014).
17 Andrea Sboner et al.,The Real Cost of Sequencing: HigherThan YouThink!, 12 GENOME BIOL. 125 (2011).
18 Timothy Caulfield et al., Reflections on the Cost of ‘Low-Cost’ Whole Genome Sequencing: Framing the Health
Policy Debate, 11 PLOS BIOL. e1001699 (2013).
19 US Food and Drugs Administration, supra note 3, at 8; see alsoMary V. Relling &William E. Evans, Phar-
macogenomics in the Clinic, 526NATURE 343 (2015);QiangMa&Anthony YHLu, Pharmacogenetics, Phar-
macogenomics, and Individualized Medicine, 63 PHARMACOLOGICAL REV. 437 (2011).
20 Collins & Varmus, supra note 10, at 794.
21 Id. at 793.
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costs of developing these bespoke treatments are likely to be enormous, requiring con-
sideration of their value in meeting broader health system needs.22
Although translation into the clinic has been slow, there are a few examples of com-
bined diagnostic-therapeutic interventions that have been shown to confer significant
benefits to individual patients in the field of oncology.23 The most obvious example is
the diagnostic test for the ‘HER2’ receptor in breast cancer tumors. Once diagnosed,
HER2 positive tumors can be provided with therapeutic intervention using the anti-
cancer drug trastuzumab (sold asHerceptin byGenentech).24TheUSFood andDrugs
Administration (FDA), the administrator of the therapeutic goods registration scheme
in that country, approved supply of Herceptin for therapeutic purposes in 1998.25
Other molecular tests paired with appropriately targeted therapeutics are available for
other cancer types including malignant melanoma, colorectal cancer, and several sub-
types of leukemia and lymphoma.26
Despite this, Collins and Varmus themselves acknowledge that many more cancer
genomes will need to be analyzed and new designs of clinical trials and pre-clinical
testing will need to be developed and approved to speed the adoption of precision
therapies.27 The emergence of drug resistance in cancer cells adds a further layer of
complexity, perhaps requiring re-sequencing of some tumors.Whilst this experience in
precision oncology is likely to expand into other spheres at some stage in the future,28
broader adoption of precision medicine is still some way off.29 Isaac Kohane identifies
ten large challenges to be addressed for precisionmedicine to realize its potential.30 Al-
though he does acknowledge that these challenges are ‘surmountable’, theirmagnitude
illustrates that we should be circumspect in our expectations about the immediacy of
significant healthcare benefits arising from targeted therapies.
According to the FDA, the first challenge that must be overcome for precision
medicine to advance is scientific.31 Essentially, proof of analytic and clinical validity
and clinical utility is required. However, the FDA also recognizes that regulatory pol-
icy and management challenges are posed by these technological advances.32 Some
commentators argue that current uncertainties in regulatory requirements are deter-
ring investment in this field.This, they argue, is leading to the conclusion that there will
need to be significant changes in theway that the FDA and equivalent agencies in other
countries operate, along with ‘unprecedented cooperation across multiple centers and
22 See Tania Bubela & Christopher McCabe, Value-engineered Translation: Developing Biotherapeutics that
Align with Health-System Needs, 20(10) AM. J. MANAGED. CARE (2014).
23 US Food and Drugs Administration, supra note 3, lists recent targeted therapy approvals at 3–4.
24 JS de Bono & Alan Ashworth, Translating Cancer Research into Targeted Therapeutics, 467 NATURE 543
(2010).
25 US Food and Drugs Administration, supra note 3, at 15.
26 M Dietel et al., A 2015 Update on Predictive Molecular Pathology and Its Role in Targeted Cancer Therapy: a
Review Focusing on Clinical Relevance, 22 CANCER GENE THERAPY 417 (2015).
27 Collins & Varmus, supra note 10, at 794.
28 Id. at 794.
29 Samuel J.Aronson&HeidiL.Rehm,Building theFoundation forGenomics inPrecisionMedicine, 526NATURE
336 (2015).
30 Isaac S. Kohane, TenThings We Have To Do To Achieve Precision Medicine, 349 SCIENCE 38 (2015).
31 US Food and Drugs Administration, supra note 3, at 14.
32 Id. at 14.
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departments’.33 Such significant changes will likely require corresponding legislative
reform.34
Direct-to-consumer genomic analysis
Whilst the requirement for an appropriate quality control framework is recognized and
becoming standardized within current health care settings, the regulatory space is be-
comingmore complicated as private entities enter into the market providing direct-to-
consumer genomic analysis.Genomic analysis of particular types of biomarkers, known
as single nucleotide polymorphisms (SNPs), provides an estimate of an individual’s
risk of developing certain diseases or conditions relative to the rest of the population.35
Companies like 23andMe, the leading US-based provider of genomic analysis using
SNP arrays, offer the entirety of their analytical services directly to consumers (DTC),
including reports onhealth risk factors.Other companies providinghealth-related anal-
yses promote their services DTC but require that the test is ordered by, or the results
returned to, healthcare providers.36 In addition to health testing, companies offering
DTC testing services often offer a range of other services such as ancestry inference37
and sports-related genetic testing.38 A large spectrum of other providers exist in the
DTC space, at least some of which offer services of dubious value to consumers, adding
further layers of complexity to the ethical, legal, and social landscape.39
Notably, in late 2013, 23andMe ceased offering health related genomic analysis to
consumers following receipt of a warning letter from the FDA requiring the company
to show cause why it had not applied formarketing clearance or approval to supply this
service.40 Subsequently, inOctober 201523andMe launched a redesigned service,with
authorization from theFDA, offering over sixty ‘health, ancestry,wellness, andpersonal
trait reports’.41
33 DovGreenbaum, Policy Forum: Regulation and the Fate of PersonalizedMedicine, 14 VIRTUALMENTOR: AM.
MED. ASSOC. J. ETHICS 645 (2012).
34 Margaret F. Riley,AnUnfulfilled Promise: Changes Needed to the Drug Approval Process toMake Personalized
Medicine a Reality, 70 FOOD &DRUG L. J. 289 (2015).
35 Melanie Swan,MultigenicConditionRiskAssessment inDirect-to-ConsumerGenomic Services, 12GENET.MED.
279 (2010).
36 Eg Color Genomics promotes its tests directly to consumers who provide DNA samples directly to the
company but requires the actual ordering of the test to be done by a physician designated by the company
(https://getcolor.com) (accessed April 23, 2016).
37 Jennifer K.Wagner, Interpreting the Implications of DNAAncestry Tests, 53 PERSP. BIOL.&MED. 231 (2010);
Jennifer K. Wagner et al., Tilting at Windmills No Longer: a Data-driven Discussion of DTC DNA Ancestry
Tests, 14 GENET. MED. 586 (2012).
38 Jennifer K.Wagner&CharmaineD. Royal, Field of Genes: An Investigation of Sports-Related Genetic Testing,
2 J. PERS. MED. 119 (2012).
39 Timothy Caulfield & Amy McGuire, Direct-to-Consumer Genetic Testing: Perceptions, Problems and Policy
Responses, 63 ANN. REV. MED. 23 (2012).
40 For an account of this and other letters sent by the FDA to DTC testing companies and their implications
see: Kaye Spector-Bagdady & Elizabeth Pike, Consuming Genomics: Regulating Direct-to-Consumer Genetic
and Genomic Information, 92 NEB. L. REV. 677, 704–17 (2015).
41 23andMe, Press Release: 23andMe Launches New Customer Experience—Reports Include Carrier Sta-
tus That Meet FDA Standards, Wellness, Traits, and Ancestry, http://mediacenter.23andme.com/blog/
new-23andme/ (accessed April 23, 2016).
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Research advances—precision gene editing
In parallel with these developments in sequencing, therapeutics and DTC genomic
analysis, new trends have been emerging in the research context. Notably, there has
been vast improvement in the accuracy of artificially manipulating genes,42 particu-
larly through Clustered Regularly Interspersed Short Tandem Repeat (CRISPR) and
CRISPR associated (Cas) technology. Although still a research tool, CRISPR-Cas has
been touted as having potential clinical application in the treatment of cancer and a
range of other diseases.43 For example, this technology can also be used in iPS cells
(induced pluripotent stem cells), which are human cells (for example, skin fibroblasts)
that are re-programmed so that they can differentiate into many different cell types.44
This combination is opening up prospects for the development of gene therapies, par-
ticularly for blood-borne disorders but also other diseases.45 Despite CRISPR-Cas’s
reported accuracy, however, there remain concerns that it could have off-target effects,
potentially risking the activation of genes that trigger cancer formation.46 Whilst ad-
vances are beingmade in identifying these effects,more comparative research is needed
to understand how best to predict andminimize them.47 These technological advances
in gene editing have re-opened debates about the efficacy of therapeutic germline gene
therapy48 and deeper philosophical discussions around the manipulation of human
embryos.49
Biobanking and data sharing in a commercialized research environment
Disease-specific andpopulation biobanks have been established inmanywestern coun-
tries to provide annotated collections of tissue, genomic data, and clinical informa-
tion to researchers, through various combinations of public, charitable, and commer-
cial funding.50 The combined power of high throughput sequencing and electronic
health records can now be harnessed to create opportunities to better understand ge-
netic determinants of disease and health outcomes.51 Together, they provide the essen-
tial resources and services for medical research into major diseases including cancer,
cardiovascular disease, mental health disorders, and diabetes. Increasingly, we are
42 David BT Cox, Randall J. Platt & Feng Zhang, Therapeutic Genome Editing: Prospects and Challenges, 21
NAT. MED. 121 (2015).
43 Genome Editing: the Age of the Red Pen, THE ECONOMIST, 22 Aug., 2015.
44 Akitsu Hotta & Shinya Yamanaka, From Genomics to Gene Therapy: Induced Pluripotent Stem Cells Meet
Genome Editing, 49 ANN. REV. GENET. 4.1 (2015).
45 Id.
46 VivienMarx,Gene Editing: How To Stay On-target with CRISPR, 11 NAT. METHODS 121 (2014).
47 See eg Richard Gabriel, Christof von Kalle & Manfred Schmidt, Mapping the Precision Of Genome Edit-
ing, 33 NAT. BIOTECHNOLOGY 150 (2015); Richard L. Frock et al., Genome-wide Detection Of Dna Double-
Stranded Breaks Induced By Engineered Nucleases, 33 NAT. BIOTECHNOLOGY 179 (2015); Shengdar Q. Tsai
et al., GUIDE-seq Enables Genome-Wide Profiling Of Off-Target Cleavage By Crispr-Cas Nucleases, 33 NAT.
BIOTECHNOL. 187 (2015).
48 Edward Lanphier et al.,Don’t Edit the Human Germ Line, 519 NATURE 410 (2015).
49 David Cyranoski & Sara Reardon, Chinese Scientists Genetically Modify Human Embryos, NATURE
DOI:10.1038/nature.2015.17378 (2015).
50 See generally, ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT, CREATION AND GOVER-
NANCE OF HUMAN GENETIC RESEARCH DATABASES (2006).
51 Wei-Qi Wei & Joshua C. Denny, Extracting Research-quality Phenotypes from Electronic Health Records To
Support Precision Medicine, 7 GENOMEMED. 41 (2015).
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seeing harmonization of biobank collections and coordination of research efforts inter-
nationally to increase the power of these rich bioresources and related infrastructure.52
Whilst significant research advances have been made since the Human Genome
Project commenced some 25 years ago,53 much is still unknown about the implications
of the multifaceted nature of gene and environment interactions on human health and
wellbeing. We still have no clear understanding of the role of many genetic variants
in human health and disease.54 There is growing recognition of the value of data shar-
ing in increasing our overall understanding of the human genome and facilitating the
translation from early and later phases of research to clinical practice.55 A range of or-
ganizations, including the International CancerGenomeConsortium,56 theGlobal Al-
liance forGenomics andHealth,57 and projects like theOpenHumansNetwork58 have
developed policies to promote the exchange of data. Data sharing does, however, be-
come particularly complex for large-scale projects involving multiple players across ju-
risdictions and cultures.59
Aside from public collections, pharmaceutical companies have maintained their
own private collections of human biospecimens from clinical trials for many years, but
these have largely been unavailable to external users.60 In addition, someDTC compa-
nies, such as 23andMe, are using their databases to engage in research programs, both
independently and in collaborationwith biotechnology andpharmaceutical companies
and public research organizations.61 Even more recently, there has been an indication
that 23andMe is launching itself into the drug discovery environment.62
These developments are raising questions about how to provide appropriate over-
sight of research in light of the collapsing of traditional boundaries between: the re-
search institution and the clinic; the patient, the research participant, and the con-
sumer; the public and commercial research sectors; and the diagnostic and therapeutic
sectors. Patients, research participants, and consumers are also increasingly expected to
be active participants in precisionmedicine rather than passive subjects or recipients of
its benefits (and arguably increasingly burdened with expectations of engagement).63
52 See eg Gert-Jan B. van Ommen et al., BBMRI-ERIC as a Resource for Pharmaceutical and Life Science Indus-
tries: the Development of Biobank-based Expert Centres, 23 EUR. J. HUM. GENET. 893 (2015).
53 Eric D. Green, James D.Watson& Francis S. Collins,Human Genome Project: Twenty-five Years of Big Biol-
ogy, 526 NATURE 29 (2015).
54 Heidi L. Rehm et al., ClinGen—the Clinical Genome Resource (2015) 372 NEW ENG. J. MED. 2235 (2015).
55 Barbara R. Jasny,Realities of Data Sharing Using the GenomeWars as a Case Study—anHistorical Perspective
and Commentary, 2:1 EPJ DATA SCI. DOI 10.1140/epjds13 (2013).
56 See http://icgc.org (accessed April 23, 2016).
57 See http://genomicsandhealth.org/ (accessed April 23, 2016).
58 See https://www.openhumans.org/ (accessed April 23, 2016).
59 Don Chalmers, Dianne Nicol &Margaret Otlowski, To Share or not to Share: Is the Question, 3 APPLIED &
TRANSL. GENOM. 116, 116–9 (2014).
60 Mary Anderlik, Commercial Biobanks and Genetic Research: Ethical and Legal Issues, 3 AM. J. PHARMACOGE-
NOMICS 203 (2003).
61 See eg 23andMe, 23andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc, Press Release,
http://mediacenter.23andme.com/blog/23andme-launches-the-lupus-research-study-in-collaboration-
with-pfizer-inc/ (accessed April 23, 2016).
62 Kelly Servick, Can 23andMe Have It All? 349 SCIENCE 1472 (2015).
63 Yann Joly et al.,TheEthical Framing of PersonalizedMedicine, 14 CURR. OP. ALLERGY&CLIN. IMMUNOLOGY
404 (2014).
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Precision medicine heightens many of the concerns about ethical, legal, and social
implications (ELSI) raised during the course of the Human Genome Project and be-
yond.64 The linkage of genotype and phenotype, past medical history, lifestyle, and
other personal information, raises particular concerns around consent, privacy, and
confidentiality, together with obvious practical questions about the accuracy, safety,
and clinical validity of the therapeutic products.These and other ELSI come into sharp
focus as precision medicine advances, with the proliferation in the amount of informa-
tion potentially available, the scale of linkage, and the untested nature of many of the
claimed therapeutic outcomes.65
DROWNING IN THE REGULATORY SOUP?
Regulating across areas of emerging or rapidly developing technologies with evolving
industry structureswill always present unique challenges.66 Regulationmust be respon-
sive to technological developments and as future-proofed as possible, if it is to have
a chance of ‘leading’. In a world of increasingly porous borders and increased partici-
pation in the borderless online world, regulation must be accommodating of differing
cultural norms, not just within, but amongst individual countries or regions.67 This is a
tall order for any regulator when the landscape and the key participants keep changing.
These regulatory challenges need not—and probably should not—result in new,
highly targeted laws, which are liable to be outpaced by scientific change. Instead, and
to the greatest extent possible, precisionmedicine shouldbe regulatedby the largebody
of existing laws and other regulatory instruments that apply to other aspects of clinical
care and medical research. Nor should it be used as a justification for recalibration of
high-level ethical principles such as those containedwithin theDeclaration ofHelsinki,
with the potential of undermining the current authority of those principles.68 Whilst
precision medicine might be scientifically new, it exists within these well-established
regulatory and oversight systems.
Someof themost relevant broadly-based regulatory and legal requirements include:
consumer protection legislation designed to ensure product safety and prevent false or
misleading marketing; privacy legislation that protects personal medical information;
and established duties of care and consent requirements with remedies for breaches
(for example, the torts of trespass and negligence). There are also a number of specif-
ically designed regulatory regimes relating to drug approvals, diagnostic testing, and
research. Their adequacy and appropriateness with regard to some of the key features
of precision medicine is discussed further below.
Specific regulatory challenges for pharmacogenomics
Pharmacogenomics is positionedwithin the regulatory andoversight system formarket
approval of therapeutic goods.The current model for regulating drug approvals clearly
has inadequacies in this space because the evidence upon which decisions are made
64 Chalmers et al., supra note 7, at 578; Brothers and Rothstein, supra note 6, at 43.
65 For a recent perspective on ELSI of precision medicine see: Ian VMcGonigle,TheCollective Nature of Per-
sonalized Medicine, 98 GENET RES, CAMB e3 (2016).
66 See eg Editorial,Direct-to-consumer Genetic Testing, 380 THE LANCET 76 (2012).
67 See Brownsword &Goodwin, supra note 5, at 47.
68 Joseph Millum, David Wendler & Ezekiel J. Emanuel,The 50th Anniversary of the Declaration of Helsinki:
Progress but Many Remaining Challenges, 310 JAMA 2143 (2013).
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comes from large randomized clinical trials.69 The system is simply not designed with
personalized treatments in mind.70 In response to these and other pressures, govern-
ments in a number of jurisdictions are examining reform options from both the regula-
tory perspective (for example, through adaptive licensing) and the funding perspective
(including performance-based risk sharing agreements).71 Concerns have been raised
as to whether these proposed reforms can be implemented successfully, with commen-
tators urging that they should be ‘approached with a healthy degree of skepticism’.72
Other commentators posit that what is needed is a new approach of hypothesis-
testing clinical trials, arguing that analytical validation of biomarker assays will be a
key component.73 In this regard, note should be taken of the work of the International
Conference on Harmonization, which is attempting to formulate mutually agreed
biomarker qualification standards between the European Union, USA, and Japan.74
The FDA itself has recognized that one of the significant challenges in approvals for
targeted therapies and companion diagnostics is that the products are regulated by dif-
ferent FDACenters and often sponsored by different companies.75 The FDAhas taken
some modest steps in response, but recognizes that more will need to be done.76
Regulating direct-to-consumer genomic analysis
Genetic diagnostic testing is subject to a range of specific regulatory instruments. For
instance, theUS-based genetic diagnostic testing sector is subject to laboratory accred-
itation at the state level and through the Centers of Medicare and Medicaid Services,
as well as market clearance and approval for in vitro devices (IVDs) through the FDA.
Other jurisdictions have similar regulatory requirements.77
As precision medicine moves further into a world of DTC delivery, consumers can
increasingly bypass traditional healthcare systems and healthcare providers in favor of
these commercial offerings.78 While existing consumer protection regulatory frame-
works may already adequately cover products made directly available to consumers,
they do not necessarily provide the same level of protection in relation to DTC ser-
vices.79 Concerns have long been expressed about the accuracy of the predictionsmade
69 de Bono & Ashworth, supra note 24, at 543; Shannon G. Gibson & Trudo Lemmens, Niche Markets and
Evidence Assessment in Transition: a Critical Review of Proposed Drug Reforms, 22 MED. L. REV. 200 (2014).
70 Riley, supra note 34, at 290; see alsoWNicholson Price III,Black-boxMedicine, 28HARV. J. L.&TECH. 419,
426 (2015).
71 Gibson & Lemmens, supra note 69, at 209–211.
72 Id. at 219.
73 de Bono & Ashworth, supra note 24, at 545–547.
74 Stuart Hogarth, Regulatory Experiments and Transnational Networks: the Governance of Pharmacogenomics
in Europe and the United States, 25(4) INNOVATION—EUR. J. SOC. SCI. RES. 1 (2012).
75 US Food and Drugs Administration, supra note 3, at 56, 57, at 32, 35.
76 For example, in 2012 the FDA established the Office of Combination Products in 2012, Id. at 16.
77 US Food and Drugs Administration, supra note 3, at 56, 57; Dianne Nicol & Meredith Hagger, Direct To
ConsumerGenetic Testing—ARegulatoryNightmare? 198MED. J.AUSTL. 501 (2013); StuartHogarth,David
E. Barton &DavidMelzer,The European IVD Directive and Genetic Testing’ in QUALITY ISSUES IN CLINICAL
GENETIC SERVICES 49, 62 (Ulf Kristoffersson, Jo¨rg Schmidtke & JJ Casiman eds., 2010).
78 Heidi C. Howard & Pascal Borry,Direct-to-consumer Genetic Testing: More QuestionsThan Benefits? 5 PERS.
MED. 317 (2008).
79 Caroline F.Wright, AlisonHall & Ron L. Zimmern, Regulating Direct-to-consumer Genetic Tests: What is all
the Fuss About?, 13 GENET. MED. 295 (2011).
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byDTC testing companies,80 and consumer ability to understand and interpret test re-
sults, particularly in an environment where there is typically no genetic counseling.81
It should be noted, however, that a robust evidence base of documented harms is still
lacking.82 Moreover, the nature of some of these harms is contestable, with some com-
mentators arguing that adults, as healthcare consumers, should have the freedom to
choose whether or not to access these services, and indeed that they have the right to
access and possess their health data.83
One recent extension of regulatory oversight has been to include laboratory-
developed tests (LDTs) within the IVD regulatory framework.84 In the USA, the FDA
is still in the process of developing this framework for oversight of LDTs, and once fur-
ther developed may face legal challenge.85
Regulating the evolving research space
Publicly funded researchers and public research institutions are bound by national
codes of research ethics; and in the clinic, health care practitioners are bound by pro-
fessional and ethical codes of conduct. These ‘soft’ laws can provide more nuanced
assistance in guiding ethical conduct than blunt legislative intervention. But it is per-
haps in these areas that the regulatory puzzle is most perplexing. In the era of preci-
sion medicine, where the traditional boundaries around public research and profes-
sional care are being transcended,86 can these soft laws be adapted to suit this new
environment? There is a risk that these soft laws could actually create more layers of
regulatory complexity and confusion in this multidisciplinary area, given that different
professions have different codes of conduct, and that a substantial body of hard laws is
already in existence. Thus, achieving regulatory consistency in this cross-disciplinary,
cross-jurisdictional space, positioned between the public and private sectors, will be
challenging.
National ethical research codes, which put the responsibilities associated with ap-
proval and compliance on institutions, are not a good fit for collaborative research that
crosses institutional and disciplinary boundaries because research teams inevitably face
review by a multitude of institutional research ethics committees (referred to as Insti-
tutional Review Boards in the US). This problem has already been recognized by the
US Department of Human and Health Services (DHHS) in its review of the Federal
80 See eg Gregory Kutz (United States Government Accountability Office),Direct-to-consumer Genetic Tests:
Misleading Test Results Are Further Complicated by Deceptive Marketing and Other Questionable Practices,
July 2010; Rachel Kalf et al., Variations in Predicted Risks in Personal Genome Testing for Common Complex
Diseases, 16 GENET. MED. 85 (2014).
81 Alice K. Hawkins & Anita Ho, Genetic Counseling and the Ethical Issues Around Direct to Consumer Genetic
Testing, 21 J. GENET. COUNSELING 367 (2012).
82 Timothy Caulfield, Direct-to-consumer Testing: If Consumers Aren’t Anxious, Why Are Policymakers? 130
HUM. GENET. 23 (2011).
83 See eg Robert Green & Nita Farahany,The FDA Is Overcautious on Consumer Genomics, 505 NATURE 286
(2014).
84 Barbara J. Evans,TheLimits of FDA’s Authority to Regulate Clinical Research involving High-throughput DNA
Sequencing, 70 FOOD &DRUG L. J. 259 (2015); Nicol &Hagger, supra note 77, at 502.
85 US Food and Drugs Administration, supra note 3, at 32.
86 See eg JOEALPER&CLAUDIAGROSSMANN, RAPPORTEURS; IOMROUNDTABLE ONVALUE&SCIENCE-DRIVEN
CARE; INSTITUTEOFMEDICINE, INTEGRATINGRESEARCHANDPRACTICE:HEALTHSYSTEMLEADERSWORKING
TOWARD HIGH-VALUE CARE: WORKSHOP SUMMARY (2015).
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Policy for the Protection of Human Subjects (also known as the Common Rule).87
The situation becomes even more complex for multinational data sharing projects.88
The US FDA is starting to discuss oversight of genome sequencing techniques, be-
cause of concerns about how tomeasure their analytical and clinical validity in this con-
text.89 This is raising concerns about the consequences of the FDAmoving into the re-
search space, and the constitutional authority for it to do so.90 Barbara Evans notes that
despite the FDA’s good intentions, this move into the research space has the potential
to slow the progress of genomic discovery, interfere with scientific inquiry and freedom
of speech, and upset the primacy of the states to regulate medical practice.91
In the context of gene editing, there is a developing body of bioethics literature.92
Discussions are also beginning about the need for model regulatory frameworks that
balance research and practice, with particular focus on research involving human em-
bryos.93 This is an area where there is consensus that the law must keep pace with
the technology, but also recognition that rushing to regulate is not always the best ap-
proach.94 A recent review of the international regulatory landscape revealed a patch-
work of approaches, ranging from absolute prohibition of clinical germline gene ther-
apy applications to non-enforceable guidelines.95 The need for clarity and consistency
is prompting policy makers to reevaluate the adequacy of their regulatory responses.96
This is an area of genetic technology where self-regulation has, in the past, played
a significant role. In the early 1970s, recombinant DNA technology was beginning to
be adopted as a viable research tool. The scientific community took the lead in impos-
ing their ownmoratorium on certain research uses of this technology.97 Subsequently,
in 1975, leading scientists in the field met at the International Conference on Recom-
binant DNAMolecules (the Asilomar Conference). They agreed that some aspects of
researchusing recombinantDNAtechnology shouldbe allowed toproceed, on thepro-
viso that stringent safeguards were in place, but there remain ‘certain experiments in
87 US Department of Health and Human Services, NPRM 2015—Summary, 2015, http://www.hhs.gov/
ohrp/humansubjects/regulations/nprm2015summary.html (accessed April 23, 2016); see also Ann-
Margret Ervin et al., Evidence Gaps and Ethical Review of Multicenter Studies, 350 SCIENCE 632 (2015).
88 This is an area of activity for theGlobal Alliance for Genomics andHealth (G4GH) EthicsWorkingGroup
Ethics Review Equivalency Task Team, which is developing models that allow for mutual recognition
of ethics review, https://genomicsandhealth.org/working-groups/our-work/ethics-review-equivalency
(accessed April 23, 2016).
89 US Food and Drugs Administration, supra note 3, at 31; Evans, supra note 84, at 259, 260.
90 Evans, supra note 84, at 260, 261.
91 Id. at 260, 261.
92 Eg the American Journal of Bioethics dedicated a whole issue in its 2015 volume to this topic:
http://www.tandfonline.com/toc/uajb20/15/12 (accessed April 23, 2016).
93 The Hinxton Group, Statement on Genome Editing Technologies and Human Germline Genetic Modification
(2015); Debra JHMathews, et al., A Path through theThicket, 527 NATURE 159 (2015).
94 Eli Y. Adashi & I Glenn Cohen, Editing the genome of the human germline: may cool heads prevail, 15 AM. J.
BIOETHICS 40 (2015).
95 MotokoAraki&Tetsuya Ishii, International Regulatory Landscape and Integration of CorrectiveGenomeEdit-
ing into In Vitro Fertilization, 12 REPROD.BIOL.&ENDOCRINOLOGY 108 (2014). See alsoHeidi Ledford,The
Landscape for Human Genome Editing, 526 NATURE 310 (2015).
96 Ledford, supra note 95, at 310.
97 Paul Berg et al., Summary Statement of the Asilomar Conference on Recombinant DNA Technology, 72 PROC.
NATL. ACAD. SCI. USA 1981 (1975).
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which the potential risks are of such a serious nature that they ought not to be done
with presently available containment facilities’.98
Moving to 2015, a groupof scientists, including someof the participants at theAsilo-
marConference, came together early in the year to discuss the same types of issueswith
regard to the latest technological developments in gene editing, with particular focus
on CRISPR-Cas.99 As with Asilomar participants, this group urged cautious adoption
of gene editing technology, with particular focus on transparency and open discussion
of the merits and risks, and strongly discouraged the use of this technology in germline
genome modification.100 Quite how well the self-regulatory approach that was so suc-
cessful in the 1970s can work in themodern research environment is open to question.
It is notable that the participants at the 2015 meeting were all US-based scientists.The
research world was a more uniform place back in the time of Asilomar—now new re-
search powerhouses like China will make self-regulation and international harmoniza-
tion more difficult.
More recently, the US National Academy of Sciences and the National Academy
of Medicine hosted an international summit as part of their Human Gene-Editing Ini-
tiative. The application of somatic gene editing was endorsed in a statement released
following the conclusion of the summit, but the same could not be said for germline
editing.101 The statement highlighted that it would be irresponsible to proceed with
clinical use of germline editing without resolution of safety and efficacy issues, societal
consensus, and appropriate regulatory oversight.102
Regulating biobanking and data sharing
Biobanking and data sharing are heightening ongoing concerns about the nature of
the consent process for future unspecified research uses of tissue and genetic data.
The establishment of large-scale population-wide biobanks led to a rush of policy
statements103 and practical guidelines.104 Some biobanks have also developed their
own ethics and governance frameworks.105 Yet, by their nature, biobanks are not
able to fully inform participants at the time when they are asked to consent to par-
ticipate about matters such as future research opportunities, tissue and data shar-
ing partners, return of research results and incidental findings,106 and commercial
98 Id. at 1981.
99 SeeDavid Baltimore et al.,APrudent Path Forward forGenomic Engineering andGermlineGeneModification,
348 SCIENCE 36 (2015).
100 Id. at 37.
101 Organizing Committee for the International Summit onHumanGene Editing, International Summit State-
ment, 3Dec. 2015, http://www8.nationalacademies.org/onpinews/newsitem.aspx?RecordID=12032015a
(accessed April 23, 2016).
102 Id.
103 Eg HUMAN GENOME ORGANISATION ETHICS COMMITTEE, STATEMENT ON HUMAN GENOMIC DATABASES
(2003); OECD, GUIDELINES FOR HUMAN BIOBANKS AND GENETIC RESEARCH DATABASES (2009).
104 ISBER, Best Practices for Repositories I: Collection, Storage, and Retrieval of Human Biological Materials for
Research, 3 CELL PRESERV. TECH. 5 (2005); NATIONAL CANCER INSTITUTE, FIRST-GENERATIONGUIDELINES
FOR NCI-SUPPORTED BIOREPOSITORIES (2006).
105 UK BIOBANK, ETHICS AND GOVERNANCE FRAMEWORK, VERSION 2.0 (2006).
106 The issue of return of research results becomes even more complex from the perspective of relatives of re-
search participants. See SusanM.Wolf et al.,Returning a Research Participant’s Genomic Results to Relatives:
Analysis and Recommendations, 43 J. L. MED. & ETHICS 440 (2015).
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relationships.107 A newmodel of ‘broad’ consent was developed especially for biobank-
ing to deal with these practical difficulties.108 Some commentators, particularly Tim
Caulfield and Jane Kaye, remain unconvinced that the justifications for this move away
from traditional notions of consent are adequate.109 In response, new consent mod-
els are being developed, such as dynamic consent,110 which uses online digital tech-
nologies to communicate and engage with participants and to provide them with the
information needed to give an informed consent in a changing research environment.
Others have suggested discarding the consent model altogether in favor of a property
approach, which employs the gift relationship as the basis of biobanking.111 It is note-
worthy that in the USA theDHHS review of the CommonRule favors a broad consent
model with regard to the collection of biospecimens,112 although that seismic shift in
policy remains highly controversial. The regulatory challenges in data sharing extend
beyond the issue of consent to privacy and data protection, particularly when data is
released into the public domain.113 A key challenge is to ensure risk management min-
imizes the risk of harm from sharing of genomic data for participants and for their rela-
tives.These dual risks arise because of the features genomic data that implicate distinct
individual and collective interests.114
Another emerging governance issue is the question of who should have access to
biobank resources and on what terms. One key issue is whether differential fees should
be charged for access by for-profit and non-profit entities. In Genomics England’s cur-
rent industry trial of access to data in its ‘100,000 Genomes Project’, companies have
to pay a fee to join a consortium before they can access any data.115 This access regime
contrasts quite dramatically to those of other biobanks.UKBiobank, for example, oper-
ates on a cost-recovery basis regardless of research purpose.116 Whilst the types of data
and tissue that are available for access at different biobanks vary considerably and will
inevitably be of different value, governing bodies should be careful to ensure that any
access policy they put in place does not unduly compromise access to these invaluable
resources. Indeed, this type of ‘regulation’ has the ability to slow the genomic discovery
process just as much as any other formalized regulatory requirement.
107 Timothy Caulfield et al., A Review of the Key Issues associated with the Commercialization of Biobanks, 1 J. L.
& BIOSCI. 94 (2014).
108 Christine Grady et al., Broad Consent for Research with Biological Samples: Workshop Conclusions, 15 AM. J.
BIOETHICS 34 (2015).
109 Timothy Caulfield & Jane Kaye, Broad Consent in Biobanking: Reflections on Seemingly Insurmountable
Dilemmas, 10 MED. L. INT’L 85 (2009).
110 Jane Kaye et al.,Dynamic Consent: a Patient Interface for Twenty-First Century Research Networks, 23 EUR. J.
HUM.GENET. 1 (2014);HawysWilliams et al.,Dynamic Consent: A Possible Solution to Improve Patient Con-
fidence and Trust in How Electronic Patient Records Are Used in Medical Research, JMIR MED. INFORMATICS
DOI 10.2196/medinform.3525 (2015).
111 Cameron Stewart et al.,The Problems of Biobanking and the Law of Gifts, in PERSONS, PARTS AND PROPERTY:
HOWSHOULDWEREGULATEHUMANTISSUE INTHE21STCENTURY? 25, 38 (ImogenGoold et al. eds., 2014).
112 US Department of Health and Human Services, supra note 87.
113 See for example, Wolf et al., supra note 106, at 445; ALONDRA NELSON, THE SOCIAL LIFE OF DNA: RACE,
REPARATIONS, AND RECONCILIATION AFTER THE GENOME (2016).
114 Chalmers, Nicol &Otlowski, supra note 59, at 116, 119.
115 Genomics England, A Framework for Industry Engagement, Mar. 2015, at 5 and 6.
116 UK Biobank, Principles of Access, http://www.ukbiobank.ac.uk/principles-of-access/ (accessed April 23,
2016).
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Other regulatory tools
Research funding, health care reimbursement schedules, and insurance coverage must
be recognized as key components of the regulatory framework. Although perhaps
not traditionally thought of as regulatory instruments as such, each of these is rele-
vant because it has the capacity to channel group behavior, thereby coming within
Brownsword and Goodwin’s definition of regulation. Regulatory theorists have long
accepted that there ismore to regulation than laws andother regulatory instruments.117
For instance, reimbursement will only be provided for new genetic tests if there is clear
evidence of analytical validity, clinical validity, and clinical utility.118 Essentially, in such
circumstances, reimbursers become de facto regulators, fulfilling like functions.119
Other legal regimes, including the patent system, also have a regulatory function in
this space, particularly with respect to diagnostic testing. Perhaps inadvertently, recent
decisions of the US Supreme Court and the Australian High Court redefining the legal
requirements for patentable subjectmatter120 may have the effect of increasing the reg-
ulatory burden on the FDA and others. The reason for this suggestion is that removal
of the threat of patent infringement will likely open up the diagnostic testing market to
new entrants. In the past, the grant of patents claiming rights to nucleotide sequences
and associated diagnosticmethods created de facto barriers to entry into the genetic di-
agnostic testingmarket, either through actual instances of patent enforcement, or fears
fromdiagnostic testing laboratories that they at any timecould facepatent infringement
lawsuits. As noted in the recent Report on Confirmatory Genetic Diagnostic Test Activity
by the US Patent and Trademarks Office, these cases have ‘dramatically affect[ed] the
landscape of diagnostic testing’.121 Although the Report focuses specifically on con-
firmatory (or second opinion) tests, it illustrates the point that the gatekeeping role
of gene-based patents has been largely extinguished. The Report concludes that this
changing landscape will result in many smaller providers entering the market.122 This
will be beneficial to consumers, if it increases choice and decreases cost, but may in-
crease the burden on regulators in ensuring regulatory compliance as the number of
providers expands. Moreover, the gatekeeper role could shift to the insurer to make
choices around suchquestions aswhich tests fromwhich laboratories should be eligible
for reimbursement. However, to date only the US and Australian courts have ruled on
the ineligibility of nucleotide sequence patents based on the subject matter ground. In
Europe, provisions in the European BiotechnologyDirective (particularly Article 5)123
make it difficult for legal actions seeking to invalidate nucleotide sequence claimson the
117 See eg John Braithwaite,The Essence of Responsive Regulation 44 UBC L. REV. 475 (2011).
118 Patricia A Deverka & Jennifer C. Dreyfus, Clinical Integration of Next Generation Sequencing: Coverage and
Reimbursement Challenges, 42 J. L., MED. & ETHICS 22, 23 (2014).
119 Id. at 25; J Larry Jameson & Dan L. Longo, Precision Medicine—Personalized, Problematic and Promising
372 NEW ENG. J. MED. 2229, 2233 (2015).
120 In the USA, see particularlyMayo Collaborative Services v. Prometheus Laboratories, Inc., 132 S. Ct. 1289
(2012) and Association for Molecular Pathology v. Myriad Genetics, Inc., 132 S.Ct. 1794 (2012); in Aus-
tralia, see d’Arcy vMyriad Genetics, Inc [2015] HCA 35.
121 US PATENT AND TRADEMARKS OFFICE, REPORT ON CONFIRMATORY GENETIC DIAGNOSTIC TEST ACTIVITY,
12 (2015).
122 Id. at 32.
123 European Parliament and Council Directive 98/44/EC of 6 July 1998 on the legal protection of biotech-
nological inventions [1998] OJ L 213/13.
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subject matter ground to be brought in countries that have implemented the Directive
into their domestic patent legislation.
It is also pertinent that other intellectual property regimes are already taking the
place of patents in regulating entry of alternative providers into the diagnostic testing
market. Companies that have been offering diagnostic tests exclusively for a number
of years in reliance on their patent rights, now have extensive databases of population-
wide genetic data, which are used to compare genetic variations of otherwise unknown
significance with particular disease manifestations.124 Trade secrecy laws allow them
to keep their data confidential. Circumventing this proprietary database dilemma will
require creation of an equivalent public access dataset.125 This will take time, and in the
interimprivate companieswill still exert a powerful influence in regulatingmarket entry
of other providers.
Theregulatory soup
Figure 1 illustrated how the traditional boundaries between the clinic, the research lab
and the different industry sectors are breaking down. One consequence is that the de-
fined regulatory spaces within which each of these sectors operate become a diffuse
regulatory soup, as illustrated in Fig. 2.
The first task in responding to President Obama’s call to modernize the current reg-
ulatory landscape is not so much about adding further ingredients to this regulatory
soup, but working out how to engage with, interpret and, where necessary, expand ex-
isting ingredients in new areas of technology. Equally important, this task will require
us to work out how to avoid overlap and duplication. Relevant questions to consider
when assessing the reach of regulation include (but are not limited to): what are the
regulatory requirements for approval of targeted therapies that provide an appropriate
balance between incentivizing innovation and ensuring that clinical validity and patient
safety requirements are satisfied;126 should DTC companies that provide risk reports
based on SNP analysis be regulated in the same way as more conventional providers of
genetic diagnostic services; and how should genomic research be regulated, in light of
these collapsing boundaries?
THE REGULATORY FUTURE− CAN REGULATION BE EFFECTIVE?
As noted byCollins and Varmus, the regulatory challenge is to find a way of supporting
innovation and ensuring that the technology is safe and effective, and also cost effec-
tive.127 While there is a tendency to criticize the law for ‘limping behind’ technology,
best practice regulation canonlybe achieved if it is informedby an appropriate evidence
base, with adequate opportunities for reflection and debate.The sector needs to remain
adaptive, flexible and responsive to change and new research and clinical opportunities.
124 Robert Cook-Deegan et al.,TheNext Controversy In Genetic Testing: Clinical Data As Trade Secrets 21 EUR.
J.HUM.GENET. 585 (2013); JohnM.Conley, Robert Cook-Deegan&Gabriel Luzaro-Munoz,Myriad after
Myriad:The Proprietary Data Dilemma, 15 N. C. J. L. & TECH. 597, 613 (2014).
125 Id.
126 See Reza Mirnezami & Jeremy Nicholson, Preparing for Precision Medicine, 366 NEW ENG. J. MED. 489
(2012); Eric S. Lander, Cutting the Gordian Helix—Regulating Genome Testing in the Era of Precision
Medicine, 372 NEW ENG. J. MED. 1185 (2015).
127 Collins & Varmus, supra note 10, at 795.
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Figure 2. The changing regulatory soup engulfing precision medicine. A. Traditional
circumscribed regulatory instruments. B. Breaking down of the boundaries of traditional
regulatory instruments.
Caution is required in law reform relating to precision medicine, lest we fall victim to
genetic exceptionalism, which might introduce more problems than it resolves.128
Scope and context
It is not yet clear, whether effective implementation of precision medicine will require
a different approach to howwe apply and use regulation thanwhat is currently the case.
Who and what we regulate clearly needs to be in scope—is it tests and healthcare
products or is it professional and research practice, or all of these? This affects what is
128 Thomas Murray, Genetic Exceptionalism and ‘Future Diaries’: Is Genetic Information Different From Other
Medical Information? inGENETICSECRETS:PROTECTINGPRIVACYANDCONFIDENTIALITY INTHEGENETICERA
60 (M Rothstein ed., 1997).
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regulated and who the regulator will be. The question is not how to regulate, but how
to regulate well.129 In this regard, Stuart Hogarth points to the central role played by
regulatory agencies in the productionof newhealthcare technologies, like pharmacoge-
nomics, and in the creation of new regulatory spaces.130 Hogarth and others emphasize
the importance of developing agreed sets of standards, whether internationally,131 or
nationally.132 Those proposing new regulatory structures or approaches must be cog-
nizant of the governance and cultural contexts in which they are to be introduced.
Precisionmedicine and society
In light of the increasing translation of genomic research results into clinical practice,
there have been grander calls for a recasting of science’s contract with society, in a way
that emphasizes reciprocity and meeting public needs. This should not simply entail
disseminationof information to educatemembers of the public about the role precision
medicine in modern healthcare, but genuinely engaging with them to understand how
they view the promises and problems of these technological developments.133
While education is one of the softer regulatory tools, sitting firmly at the base of Ay-
ers and Braithwaite’s responsive regulatory pyramid,134 it seems clear that educational
tools need to be improved. This should preferably occur ‘before’ an individual is sit-
ting in a doctor’s office facing a potentially serious or traumatic medical decision about
himself/herself or a loved one. How do we improve genetic education so that all even-
tual patients, prospective research participants, and consumers of DTC services have a
reasonable, minimum understanding of human genetics and the potential capacity and
limits of precisionmedicine to facilitate autonomous decision-making?What role does
or should genetic education play in managing risks of genomic medicine and research?
One tool that school and university educators are adopting to assist students with their
understanding of the complexities of genetics and genomics is the adoption of partici-
patory or ‘experiential’ approaches.135 There are a growing number of examples of high
schools and universities offering students the opportunity to provide their DNA for ge-
nomic analysis. One empirical study has shown that many university students find it an
exciting and easier way to learn.136
Medical practitioners continue to play a dominant role at the interface between the
healthcare system and the public. Their effectiveness in advising their patients about
diagnostic and treatment options presupposes that they have the appropriate skills and
understanding to provide requisite advice. Studies undertaken in the US suggest that
many medical practitioners have large gaps in their genomic knowledge, and that they
129 Barbara J. Evans, Wylie Burke & Gail Jarvik, The FDA and Genomic Tests—Getting Regulation Right, 372
NEW ENG. J. MED. 2258, 2258 (2015).
130 Stuart Hogarth, Regulatory Experiments and Transnational Networks: the Governance of Pharmacogenomics
in Europe and the United States, 25 INNOVATION—EUR. J. SOC. SCI. RES. 1 (2012).
131 Id.
132 Isaac Chan & Geoffrey S. Ginsburg, Personalized Medicine: Progress and Promise, 12 ANN. REV. GENOM. &
HUM. GENET. 217, 231–2 (2001).
133 Joly et al., supra note 63, at 407.
134 IAN AYRES & JOHN BRAITHWAITE, RESPONSIVE REGULATION (1992).
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17 GENET. TESTING &MOLECULAR BIOMARKERS 1 (2014).
136 Id. at 1.
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‘lack the requisite knowledge . . . to provide adequate genomic testing and counsel-
ing’.137 Specialists, too, need ‘genomic’ training.138
Over-medicalization
There is a real risk that without appropriate safeguards, precision medicine may drive
defensivemedical practices, shift standards of care to expectmore rather than less inter-
vention, and produce extraneous information of uncertain clinical utility. In turn, this
could lead to a growing cohort of the ‘worried well’.139 AmyMcGuire andWylie Burke
refer to this problem in the context of DTC genomic analysis as ‘raiding the medical
commons’. They argue that the time a medical practitioner spends with a patient dis-
cussing their personal health genomic analysis reports, which continue to be of dubious
clinical value, detracts from the time that could be spent discussing othermore relevant
matters.140 Another term that has been coined to refer to those individuals who sit in
the twilight zone between sickness and health is ‘patients in waiting’.141
These scenarios raise further questions as to the kinds of information that patients
and other consumers need to make informed decisions about clinical care. There is al-
ready a growing movement in healthcare questioning ‘over-medicalization’. For exam-
ple, in Australia, the USA and Canada, the ‘Choosing Wisely’ initiative involves over
fifty medical organizations developing evidence-based recommendations for practices
or procedures that should be reconsidered or discontinued because they fail to bene-
fit, and may even harm, patients. In the UK, the British Medical Journal’s ‘Too Much
Medicine’ project focuses on the harms of over-diagnosis and unnecessary healthcare
interventions. It is timely to reflect onwhether precisionmedicinewill promote ‘appro-
priate healthcare’, recognizing that ‘toomuchmedicine is harmingboth the sick and the
well’.142
CONCLUSION
This essay has shown that responding to President Obama’s call to modernizing the
current regulatory landscape for precision medicine will be no simple task. In this era
of rapid technological change, the need for appropriate regulatory oversight is acute to
ensure that available technologies are safe and that people receive the best-indicated
treatment. There is, however, more to regulation than the (at times) blunt instrument
of the law. Softer regulatory and educative tools also need to be brought into the mix.
The key regulatory challenge is how to effectively facilitate the practice of precision
medicine, so that we maximize the potential benefits, while avoiding excessive and in-
appropriate utilization that could harm patients, drive up healthcare costs, and draw
funding away fromother needs.Whether regulation—either existing or tailor-made for
precisionmedicine—can be effective remains to be seen.The analysis presented in this
137 Ribhi Hazin et al., Ethical, Legal and Social Implications of Incorporating Genomic Information into Electronic
Health Records, 15 GENET. MED. 810, 812 (2013); See also Chan &Ginsburg, supra note 132, at 230.
138 Dietel et al., supra note 26, at 418.
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essay identifies five key recurring elements that must be taken into account in the de-
velopment of any regulatory framework for precision medicine:
(i) appropriate consideration of safety, efficacy, and patient need;
(ii) cost effectiveness;
(iii) consistency/equivalency across geographical, technological, and institu-
tional borders;
(iv) respect for cultural differences; and
(v) genuine engagement with all relevant stakeholders.
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